| Revenue growth | 25% YoY growth guided for FY27. |
|---|---|
| Margins | EBITDA margins targeted at 20-22% for FY27. |
| Order book | Stable order flows; good visibility for next 12 months. |
| Demand visibility | Strong visibility in PASC and SDA; Euro 7 norms drive SDA. |
| Management confidence | High; visibility until end of CY26 for orders. |
Growth
FY26 revenue exceeded ₹500 crores. Electrolyte Salts segment saw exceptional 1,378% YoY growth in Q4.
Outlook
FY27 guidance maintained at 25% revenue growth with 20-22% EBITDA margins. Capex of ₹100cr planned for FY27.
Risks
Geopolitical conflicts leading to rising fuel and raw material (crude/ammonia) costs; semiconductor commercialization gestation period.
Earnings Call filed with NSE, NSE: TATVA. Summary written with AI assistance from the document.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,793.20
- Market cap
- ₹4,195 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 81.6×Sector 37.5×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 3.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Investor Presentation: Key Takeaways
Tatva Chintan reported strong Q1 FY27 results with 43% YoY revenue growth. Strategy focuses on expanding SDA for Euro 7 standards and commercializing new pharma/semiconductor molecules.
- Call
- Guides 30% growth
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported strong Q1FY27 performance with 43% YoY revenue growth to ₹1,671 Mn. Strategy focuses on green chemistry, R&D in continuous flow, and electrolysis for SDAs.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported FY26 revenue of ₹5,059 Mn, up 32% YoY. Growth driven by SDA segment expansion and 'green' chemistry adoption.
Tatva Chintan Pharma Chem Earnings Call: Key Takeaways
Tatva Chintan reported a strong FY26 with revenue up 32% to ₹5,059 Mn and PAT surging 636% to ₹421 Mn. Growth driven by SDA and PASC segments.